ArticleExpert opinion on therapeutic targets2014
Could the Ebola virus matrix protein VP40 be a drug target?
Article in Expert opinion on therapeutic targets, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 55 citations in OpenAlex.
- Identification of a unique humoral immune signature of Sudan ebolavirus persistence in human survivors.Research square · 2026Article
- Minor changes in electrostatics robustly increase VP40 membrane binding, assembly, and budding of Ebola virus matrix protein derived virus-like particles.bioRxiv : the preprint server for biology · 2024Article
- In silico exploration of deep-sea fungal metabolites as inhibitor of Ebola and Marburg VP35 and VP40.PloS one · 2024Article
- Epidemiology of Ebolaviruses from an Etiological Perspective.Pathogens (Basel, Switzerland) · 2023Review
- Mechanisms of phosphatidylserine influence on viral production: A computational model of Ebola virus matrix protein assembly.The Journal of biological chemistry · 2022Article
- Protein Folding Interdiction Strategy for Therapeutic Drug Development in Viral Diseases: Ebola VP40 and Influenza A M1.International journal of molecular sciences · 2022Article
- Article
- Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application.Pathogens (Basel, Switzerland) · 2021Review
- Article
- Conformational Flexibility of the Protein-Protein Interfaces of the Ebola Virus VP40 Structural Matrix Filament.The journal of physical chemistry. B · 2019Article
- Molecular docking enabled updated screening of the matrix protein VP40 from Ebola virus with millions of compounds in the MCULE database for potential inhibitors.Bioinformation · 2019Article
- A cylindrical assembly model and dynamics of the Ebola virus VP40 structural matrix.Scientific reports · 2018Article
- Ebolaviruses: New roles for old proteins.PLoS neglected tropical diseases · 2018Review
- Graphene-VP40 interactions and potential disruption of the Ebola virus matrix filaments.Biochemical and biophysical research communications · 2017Article
- Plasma membrane association facilitates conformational changes in the Marburg virus protein VP40 dimer.RSC advances · 2017Article
- The Ebola virus protein VP40 hexamer enhances the clustering of PI(4,5)PPhysical chemistry chemical physics : PCCP · 2016Article
- Intra-host dynamics of Ebola virus during 2014.Nature microbiology · 2016Article
- Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus.Infectious diseases of poverty · 2016Article
- The Ebola Virus matrix protein, VP40, requires phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) for extensive oligomerization at the plasma membrane and viral egress.Scientific reports · 2016Article
- Investigation of the Lipid Binding Properties of the Marburg Virus Matrix Protein VP40.Journal of virology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Filoviruses are filamentous lipid-enveloped viruses and include Ebola (EBOV) and Marburg, which are morphologically identical but antigenically distinct. These viruses can be very deadly with outbreaks of EBOV having clinical fatality as high as 90%. In 2012 there were two separate Ebola outbreaks in the Democratic Republic of Congo and Uganda that resulted in 25 and 4 fatalities, respectively. The lack of preventive vaccines and FDA-approved therapeutics has struck fear that the EBOV could become a pandemic threat. The Ebola genome encodes only seven genes, which mediate the entry, replication, and egress of the virus from the host cell. The EBOV matrix protein is VP40, which is found localized under the lipid envelope of the virus where it bridges the viral lipid envelope and nucleocapsid. VP40 is effectively a peripheral protein that mediates the plasma membrane binding and budding of the virus prior to egress. A number of studies have demonstrated specific deletions or mutations of VP40 to abrogate viral egress but to date pharmacological inhibition of VP40 has not been demonstrated. This editorial highlights VP40, which is the most abundantly expressed protein of the virus and discusses VP40 as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.